515 related articles for article (PubMed ID: 9546426)
1. The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.
Pinkas-Kramarski R; Lenferink AE; Bacus SS; Lyass L; van de Poll ML; Klapper LN; Tzahar E; Sela M; van Zoelen EJ; Yarden Y
Oncogene; 1998 Mar; 16(10):1249-58. PubMed ID: 9546426
[TBL] [Abstract][Full Text] [Related]
2. Bivalence of EGF-like ligands drives the ErbB signaling network.
Tzahar E; Pinkas-Kramarski R; Moyer JD; Klapper LN; Alroy I; Levkowitz G; Shelly M; Henis S; Eisenstein M; Ratzkin BJ; Sela M; Andrews GC; Yarden Y
EMBO J; 1997 Aug; 16(16):4938-50. PubMed ID: 9305636
[TBL] [Abstract][Full Text] [Related]
3. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling.
Graus-Porta D; Beerli RR; Daly JM; Hynes NE
EMBO J; 1997 Apr; 16(7):1647-55. PubMed ID: 9130710
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors.
Alimandi M; Wang LM; Bottaro D; Lee CC; Kuo A; Frankel M; Fedi P; Tang C; Lippman M; Pierce JH
EMBO J; 1997 Sep; 16(18):5608-17. PubMed ID: 9312020
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
6. The role of erbB-2 and its ligands in growth control of malignant breast epithelium.
Lupu R; Dickson RB; Lippman ME
Princess Takamatsu Symp; 1991; 22():49-60. PubMed ID: 1688228
[TBL] [Abstract][Full Text] [Related]
7. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
Ram TG; Ethier SP
Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665
[TBL] [Abstract][Full Text] [Related]
8. Studies on the betacellulin receptor in pancreatic AR42J cells.
Ishiyama N; Kanzaki M; Seno M; Yamada H; Kobayashi I; Kojima I
Diabetologia; 1998 Jun; 41(6):623-8. PubMed ID: 9662041
[TBL] [Abstract][Full Text] [Related]
9. Betacellulin activates the epidermal growth factor receptor and erbB-4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-beta.
Riese DJ; Bermingham Y; van Raaij TM; Buckley S; Plowman GD; Stern DF
Oncogene; 1996 Jan; 12(2):345-53. PubMed ID: 8570211
[TBL] [Abstract][Full Text] [Related]
10. ErbB kinases and NDF signaling in human prostate cancer cells.
Grasso AW; Wen D; Miller CM; Rhim JS; Pretlow TG; Kung HJ
Oncogene; 1997 Nov; 15(22):2705-16. PubMed ID: 9400997
[TBL] [Abstract][Full Text] [Related]
11. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.
Karunagaran D; Tzahar E; Beerli RR; Chen X; Graus-Porta D; Ratzkin BJ; Seger R; Hynes NE; Yarden Y
EMBO J; 1996 Jan; 15(2):254-64. PubMed ID: 8617201
[TBL] [Abstract][Full Text] [Related]
12. Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4.
Komurasaki T; Toyoda H; Uchida D; Morimoto S
Oncogene; 1997 Dec; 15(23):2841-8. PubMed ID: 9419975
[TBL] [Abstract][Full Text] [Related]
13. Expression of herstatin, an autoinhibitor of HER-2/neu, inhibits transactivation of HER-3 by HER-2 and blocks EGF activation of the EGF receptor.
Azios NG; Romero FJ; Denton MC; Doherty JK; Clinton GM
Oncogene; 2001 Aug; 20(37):5199-209. PubMed ID: 11526509
[TBL] [Abstract][Full Text] [Related]
14. Reduced ability of transforming growth factor-alpha to induce EGF receptor heterodimerization and downregulation suggests a mechanism of oncogenic synergy with ErbB2.
Gulliford TJ; Huang GC; Ouyang X; Epstein RJ
Oncogene; 1997 Oct; 15(18):2219-23. PubMed ID: 9393980
[TBL] [Abstract][Full Text] [Related]
15. An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells.
Grant SL; Hammacher A; Douglas AM; Goss GA; Mansfield RK; Heath JK; Begley CG
Oncogene; 2002 Jan; 21(3):460-74. PubMed ID: 11821958
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor, platelet-derived growth factor receptor, and c-erbB-2 receptor activation all promote growth but have distinctive effects upon mouse mammary epithelial cell differentiation.
Taverna D; Groner B; Hynes NE
Cell Growth Differ; 1991 Mar; 2(3):145-54. PubMed ID: 1676295
[TBL] [Abstract][Full Text] [Related]
17. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions.
Pinkas-Kramarski R; Soussan L; Waterman H; Levkowitz G; Alroy I; Klapper L; Lavi S; Seger R; Ratzkin BJ; Sela M; Yarden Y
EMBO J; 1996 May; 15(10):2452-67. PubMed ID: 8665853
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine-phosphorylated p185erbB-2.
Ram TG; Dilts CA; Dziubinski ML; Pierce LJ; Ethier SP
Mol Carcinog; 1996 Mar; 15(3):227-38. PubMed ID: 8597535
[TBL] [Abstract][Full Text] [Related]
19. Proliferation-differentiation relationships in the expression of heparin-binding epidermal growth factor-related factors and erbB receptors by normal and psoriatic human keratinocytes.
Piepkorn M; Predd H; Underwood R; Cook P
Arch Dermatol Res; 2003 Jul; 295(3):93-101. PubMed ID: 12768307
[TBL] [Abstract][Full Text] [Related]
20. Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells.
Ram TG; Hosick HL; Ethier SP
J Cell Physiol; 2000 Jun; 183(3):301-13. PubMed ID: 10797304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
